Sunday, September 26

EANO Meeting - Sunday, September 26, 2021

All times below refer to Central European Summer Time (CEST).
Oral abstract presentations are highlighted with an A in the presentation number.

09:00-10:30 hrs

Chairs: Marjolein Geurts, Jan-Michael Werner

OS04.1 New therapies under investigation: What is TG02?
Emilie Le Rhun, France

OS04.2 Targets in Neuro-Oncology - What should we investigate next?
Simone Niclou, Luxembourg

OS04.3 New therapies under investigation: What is Marizomib?
Patrick Roth, Switzerland

OS04.4 Pitfalls in clinical trials design
Michael Weller, Switzerland

09:30-10:30 hrs

Chairs: Claudia Panciroli, Manuel Valiente

PL03.1.A Surgery for glioblastomas in the elderly: an ANOCEF trial (CSA)
Florence Laigle-Donadey, France
EANO Congress Award - Best oral presentation: Clinical research

PL03.2.A Radiotherapy is associated with a deletion signature that contributes to poor outcomes in glioma patients
Emre Kocakavuk, United States
EANO Congress Award - Best oral presentation: Basic research

PL03.3.A Development and characterization of CD317-specific CAR T cells as an innovative immunotherapeutic strategy against glioblastoma
Lena Hänsch, Switzerland
EANO Congress Award - Best oral presentation: Translational research

PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
Marijke Coomans, Netherlands
EANO Congress Award - Best oral presentation: Supportive care and quality of life research

Chairs: Antonella Castellano, Marilena Theodorou

ME03.1 Heterogenity and microstructure models with diffusion MRI
Eleftheria Panagiotaki, United Kingdom

ME03.2 Experimental new imaging in brain metastasis and translation to patients

Fabien Boux, France

ME03.3 Radiomics and AI in brain tumor imaging
Philipp Vollmuth, Germany

10:30-11:00 hrs | BREAK

11:00-12:30 hrs

Chairs: Emilie Le Rhun, Susan Short

OS05.1.A Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Matthias Preusser, Austria

OS05.2.A MGMT promoter status in IDH1/2 mutant anaplastic astrocytoma patients assessed by DNA methylation profiling and qMS-PCR: a report from the EORTC Brain Tumor Group
C. Mircea S. Tesileanu, Netherlands

OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients:translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials
Julia Furtner-Srajer, Austria

OS05.4.A Do neurocognitive deficits explain the differences between brain tumour patients and their proxies assessing the patient’s I-ADL?
Quirien Oort, Netherlands

OS05.5.A Methylation analysis of matched primary and recurrent IDHmt astrocytoma; an update from the Glioma Longitudinal Analysis NL (GLASS-NL) consortium
Wies Vallentgoed, Netherlands

OS05.6.A Detection and serial monitoring of ctDNA in breast cancer leptomeningeal disease
Amanda Fitzpatrick, United Kingdom

OS05.7.A Absence of severe hematological toxicity during first line treatment predicts low chance on severe toxicity during second line alkylating chemotherapy in glioblastoma
Femke van den Elzen, Netherlands

OS05.8.A A Phase 0/1 'Trigger' Trial of Ribociclib Plus Everolimus in Recurrent High-Grade Glioma
Nader Sanai, United States

OS05.9.A Short-term fasting in glioma patients - Analysis of diet diaries and metabolic parameters of the ERGO2 trial
Martin Voss, Germany

Chairs: Mihaela Lorger, Michael Weller

OS06.1.A non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
Pim French, Netherlands

OS06.2.A Local immunotherapy of glioblastoma via AAV-mediated gene transfer of checkpoint inhibitors in combination with CAR-NK cells
Michael Burger, Germany

OS06.3.A LSD1-directed therapy curtails glioblastoma tumorigenicity by limiting the adaptation of tumor initiating cells to stressful environments
Stefania Faletti, Italy

OS06.4.A Identification of T cell receptors targeting ZFTA-RELA fusion-positive ependymoma
Niklas Kehl, Germany

OS06.5.A Fluorescence image-guided resection of intracranial meningioma: an experimental in vivo study on nude mice
Stefan Linsler, Germany

OS06.6.A Inhibition of GBM invasion by the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist Perampanel
Katharina Sarnow, Norway

OS06.7.A METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy
Lucía Zhu, Spain

OS06.8.A Circulating extracellular vesicles as a novel tool for therapy monitoring of brain tumor patients
Franz Ricklefs, Germany

OS06.9.A Diversity of cellular communication in glioblastoma
Kevin Joseph, Germany

Chairs: Djaina Satoer, Martin Klein

OS07.1 Functional Ultrasound: the new gold standard to measure language functions during awake brain surgery?
Ellen Collée, Netherlands 

OS07.2 Trial results of ReMind: the app for cognition rehabilitiation in primary brain tumor patients
Karin Gehring, Netherlands

OS07.3 Ready, Set, Shift: intraoperative mapping of concept-shifting improves outcome
Emmanuel Mandonnet, France

OS07.4 Guess where? Mapping the cognitive interface via invasive and non-invasive imaging techniques
Constanza Papagno, Italy

OS07.5.A Diagnostic Instrument for Mild Aphasia (DIMA): sensitive and valuable addition to standard language assessment in glioma patients
Saskia Mooijman, Netherlands

12:30-14:00 hrs | BREAK

12:30-14:45 hrs

EANO Youngsters Networking Event

For more information Opens internal link in current windowclick here.

14:00-14:45 hrs

E-Poster Viewing with authors

14:45-15:00 hrs | BREAK

15:00-16:00 hrs

Chairs: Patrick Roth, Manuel Valiente

PC01.1 BBB/BTB in brain tumors (Maintained)
Patricia Steeg, United States

PC01.2 Compromised blood-brain-barrier
Patrick Wen, United States

WS03.1 How to plan your career in neuro-oncology: Neurosurgery
Marike Broekman, Netherlands

WS03.2 How to plan your career in neuro-oncology: Neuroradiology
Antonella Castellano, Italy

WS03.3 How to plan your career in neuro-oncology: Basic/Translational Research
Pim French, Netherlands

WS03.4 How to plan your career in neuro-oncology: Computational Imaging Research
Georg Langs, Austria

WS03.5 How to plan your career in neuro-oncology: Pediatric neuro-oncology
Sabine Müller, United States

WS03.6 How to plan your career in neuro-oncology: Clinical neuro-oncology
Roberta Rudà, Italy

Chairs: Simone Niclou, Felix Sahm

WS04.1 Atlas of spatially resolved multiomics in malignant brain tumours
Dieter Henrik Heiland, Germany

WS04.2 Progenitor and microenvironment diversity in gliomagenesis and therapy resistance
Q. Richard Lu, United States

16:00-16:30 hrs | BREAK

16:30-18:00 hrs

Chairs: Roberta Rudà, Wolfgang Wick

KS02.1 A novel prognostic and predictive DNA repair gene expression signature in glioblastoma
Mary-Helen Barcellos-Hoff, United States

KS02.2 DNA repair vulnerabilities in IDH mutant gliomas
Ranjit Bindra, United States

KS02.3 Clinical trials targeting the DNA damage response in glioma
Anthony Chalmers, United Kingdom

KS02.4.A Olaparib in Recurrent IDH-mutant High-Grade Glioma (OLAGLI
Francois Ducray, France

Chairs: Oliver Hanemann, Tobias Weiss

OS08.1 MR Spectroscopy for brain glioma diagnosis and therapeutic assessment
Francesca Branzoli, France

OS08.2 Integrated intraoperative diagnosis of brain tumors
Daniel Orringer, United States

OS08.3 Proteomics for brain tumor diagnosis
Andreas von Deimling, Germany

OS08.4.A Retrospective analysis of in vivo 1H-magnetic resonance spectroscopy based on a machine learning approach enables reliable prediction of IDH mutation in patients with glioma
Elisabeth Bumes, Germany

OS08.5.A Proteomic analysis of meningioma
Clemens Hanemann, United Kingdom

OS08.6.A Glioblastoma treatment response machine learning monitoring biomarkers: a systematic review and meta-analysis
Aysha Luis, United Kingdom

Chairs: Jérôme Honnorat, Riccardo Soffietti

JS05.1 Sex-based differences in Neuro-Oncology
Jill Barnholtz-Sloan, United States

JS05.2 Phase 0 and Window-of-Opportunity Trials in Neuro-Oncology
Susan Chang, United States

JS05.3 Discovery of tumor-reactive T cells in Neuro-Oncology
Michael Platten, Germany

JS05.4 Circulating Tumor DNA in Neuro-Oncology
Joan Seoane, Spain

18:00-18:30 hrs | BREAK

18:30-19:30 hrs

Chairs: Karin Piil, Kathy Oliver

ME04.1 What can the wider community learn from people living with brain cancer during COVID?
Helen Bulbeck, United Kingdom

ME04.2 The Brain Tumour Patients’ Charter of Rights
Kathy Oliver, United Kingdom

ME04.3 Brain tumours and COVID-19: the patient and caregiver experience
Mathew Voisin, Canada

Chairs: Elizabeth Cohen-Moyal, Manuel Valiente

ME05.1 Clinical implications of brain metastasis heterogeneity
Priscilla Brastianos, United States

ME05.2 Mouse models of glioma heterogeneity
Dolores Hambardzumyan, United States

ME05.3 Dissecting response to treatment in adult patients with a glioma
Roel Verhaak, United States

Chairs: Anna Golebiewska, Tobias Weiss

ME06.1 Organotypic brain tumor cultures
Simone Niclou, Luxembourg

ME06.2 3D-bioprinted models of brain tumors
Ronit Satchi-Fainaro, Israel

ME06.3 A patient-derived glioblastoma organoid model recapitulates inter- and intra-tumoral heterogeneity
Hongjun Song, United States

Note that the programme is subject to change and will be continuously updated.